Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Major Depressive Disorder AND SNRI AND SSRI antidepressants

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Major Depressive Disorder AND SNRI AND SSRI antidepressants. Displaying page 1 of 1.
    EudraCT Number: 2022-000439-22 Sponsor Protocol Number: 67953964MDD3001_VENTURA-1 Start Date*: 2023-03-08
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Multicenter, Parallel-Group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants ...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) ES (Ongoing) HU (Completed) BE (Completed) BG (Completed) PT (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000461-41 Sponsor Protocol Number: 67953964MDD3002 Start Date*: 2023-02-06
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Multicenter, Parallel-Group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants ...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) FR (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000090-23 Sponsor Protocol Number: UoB1651 Start Date*: 2013-06-19
    Sponsor Name:University of Bristol
    Full Title: Mirtazapine added to SSRIs for treatment resistant depression in primary care: a placebo controlled randomised controlled trial
    Medical condition: Treatment resistant depression
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004873 10045543 Unipolar depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000341-14 Sponsor Protocol Number: 42847922MDD3005 Start Date*: 2020-08-28
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in ...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (GB - no longer in EU/EEA) LT (Completed) LV (Completed) BE (Completed) BG (Completed) PL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2018-003251-37 Sponsor Protocol Number: ACP-103-054 Start Date*: 2019-06-11
    Sponsor Name:ACADIA Pharmaceuticals Inc
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate R...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SK (Prematurely Ended) PL (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000338-16 Sponsor Protocol Number: 42847922MDD3002 Start Date*: 2020-10-27
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Eld...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) FI (Prematurely Ended) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-005282-22 Sponsor Protocol Number: 42847922MDD2001 Start Date*: 2017-10-24
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Adaptive Dose-Finding Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) BG (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-006510-36 Sponsor Protocol Number: NL79264.091.21 Start Date*: 2021-12-21
    Sponsor Name:Radboudumc
    Full Title: Exploring the Pharmacomicrobiomics of Depression
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003073-33 Sponsor Protocol Number: MYL-1603N-3001 Start Date*: 2023-03-08
    Sponsor Name:Mylan Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Compare the Anti-Depressive Efficacy and Safety of Samyr® Tablet versus Placebo Tablet on top of Adjunctive Ant...
    Medical condition: Major Depression Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000337-40 Sponsor Protocol Number: 42847922MDD3001 Start Date*: 2020-09-10
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Eld...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000430-42 Sponsor Protocol Number: 67953964MDD3003_VENTURA-LT Start Date*: 2023-06-22
    Sponsor Name:Janssen-Cilag International NV
    Full Title: An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD)
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000399-25 Sponsor Protocol Number: ALK5461-206 Start Date*: 2014-07-09
    Sponsor Name:Alkermes, Inc.
    Full Title: A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-005200-15 Sponsor Protocol Number: 6096-022 Start Date*: 2012-05-14
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients with Major Depressive Disorder.
    Medical condition: depression
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10066555 Chronic depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) SE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2019-004264-21 Sponsor Protocol Number: 1402-0011 Start Date*: 2020-10-07
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: A Phase II, 6-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial with a quetiapine arm to evaluate the efficacy, tolerability and safety of oral BI ...
    Medical condition: Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10012401 Depressive disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) CZ (Completed) SK (Completed) DE (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-003850-21 Sponsor Protocol Number: InflaMed001 Start Date*: 2022-08-03
    Sponsor Name:Amsterdam UMC, location VUmc
    Full Title: Precision psychiatry: Anti-inflammatory medication in Immuno-metabolic depression
    Medical condition: Immuno metabolic Depression
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000043-74 Sponsor Protocol Number: PNAS0122 Start Date*: 2023-07-27
    Sponsor Name:Medical University of Vienna
    Full Title: Defining and predicting neonatal inadaptation after gestational exposure to antidepressants: longitudinal exploratory analysis of psychoneuroendocrine risk factors and complications
    Medical condition: major depressive disorder poor neonatal adaptation syndrome (after antidepressant use during pregnancy)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001884-21 Sponsor Protocol Number: CCTU0251-ATP Start Date*: 2019-06-04
    Sponsor Name:Cambridgeshire and Peterborough NHS Foundation Trust and University of Cambridge
    Full Title: A randomised, placebo-controlled, double-blind trial of the antidepressant efficacy of a novel CNS-penetrant P2X7 receptor antagonist, JNJ-54175446, in people with major depressive disorder, an inc...
    Medical condition: Major depressive disorder with an incomplete response to monoaminergic antidepressants and with biomarker profile indicative of inflammation
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 07:31:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA